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Abstract 
Tumor Microenvironment-Responsive Nanogel for Delivery of Interleukin-12                               
Dimitrios Arhontoulis  
Hao Cheng, Ph.D. 
 
 
 
 
Various forms of immunotherapy have arisen and shown promise in treating cancer. The 
administration of cytokines such as Interleukin-12 (IL-12) was thought to robustly 
stimulate innate immunity, and increase the number of endogenous tumor specific 
cytotoxic T-cells. However, patients enrolled in clinical trials involving the 
administration of IL-12 were reported to have IFNγ toxicity, and suffered from multiple 
organ system complications and in some instances, death. To address this issue, a tumor 
microenvironment-responsive nanogel composed of modified hyaluronic acid has been 
developed. This hypoxia sensitive methacrylated hyaluronic acid (HS- MAHA) aims to 
actively release IL-12 in the presence of the hypoxic tumor microenvironment, and 
eliminate the systemic toxicity exhibited in the intravenous administration of recombinant 
human IL-12. The nanogel has also shown increased degradation in the presence of 
hyaluronidase, indicating an additional component of tumor microenvironment- 
sensitivity. The nanogel is able to differentiate CD4+ T-cells into the Th1 Phenotype in 
vitro, and recruit an increased number of tumor specific cytotoxic T-cells in vivo. The 
particles have shown sufficient accumulation in the tumor, while avoiding accumulation 
in the brain, heart, and lungs. Furthermore, the administration of antiPD1 antibody in 
combination with the nanogel containing IL-12 has shown delayed tumor growth in an 
aggressive B16-F10 melanoma model.  
 
	 ix 
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Chapter 1: Introduction 
1.1 Immunotherapy Overview 
1.1.1 Cancer 
Cancer remains one of the leading causes of death in the world, accounting for over 
500,000 of deaths in the United States annually [1] From an immunological perspective, 
cancer can be considered the inability of the host immune system to eliminate mutated 
cells[2]. Standard treatments such as chemotherapy and radiation aim at eliminating the 
cells ability to replicate, and have shown efficacy in treating cancer [3]. However, due to 
their toxicity, they often cause damage to healthy cells and tissues [3]. These severely 
toxic drugs also damage cells that frequently proliferate such hair cells, cells of the 
intestinal lining, and bone marrow derived cells, creating a substantial need for a more 
robust and efficient form of cancer therapy [4]. 
 
1.1.2 Melanoma  
Melanoma is one of the most common forms of cancer in humans, especially Caucasians 
[5]. Prolonged exposure to Ultraviolet Rays from the sun is one of the largest risk factors, 
but recently, mutations in the cyclin dependent kinase inhibitor 2A locus (CDKN2A) has 
been elucidated as a major genetic basis for disease [5]. The cutaneous form melanoma 
accounts for approximately 75% of deaths related to skin cancer world wide [5]. If 
detected early, survival rates for patients with melanoma can exceed 90% [5]. However, 
patients with advanced-metastatic melanoma have a median survival time of 6-12 
months, and a survival rate of 15% or less [5]. Melanoma has exhibited complex behavior 
in terms of anti-tumor immunity evasion mechanisms, and is capable of using checkpoint 
blockades, and the up/down regulation of the Major Histocompatibility Complex (MHC) 
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to escape the host immune system [6, 7] . Figure 1 below illustrates the carcinogenesis 
process in melanocytes.  
 
 
 
 
Figure 1: A schematic of the carcinogenesis mechanism of UV radiation. Reproduced with permission from 
Schadendorf et al., 2015) Copyright© 2015, Macmillan Publishers 
 
 
 
 
1.1.3 Tumor Microenvironment 
The tumor microenvironment can be described as the interaction between malignant and 
normal cells in the surrounding tissues [8].  Other cells that are found in the tumor 
microenvironment include cells of the immune system, endothelial cells as a part of the 
tumor vasculature and lymphatic vessels, fibroblasts, pericytes and adipocytes [8]. Each 
of these types of cells contributes to a complex network of cytokines, and signaling 
	 3 
molecules that can affect immune function, angiogenesis, and other tumor associated 
metabolic pathways [8]. 
 
Tumors are able to resist the host immune system in a variety of ways that have each 
provided a series of unique challenges for clinicians and researchers. For example, 
myeloid-derive suppressor cells can help suppress immune cells that are specific for 
targeting tumor cells [9]. Tumors can also suppress T-cell function by expressing a group 
of ligands to check point blockade receptors [10]. These receptors will be elaborated in 
section 1.2.2. Furthermore, the tumor microenvironment is typically hypoxic, which 
results from an increased amount of angiogenesis and metabolic need that results from 
the tumor’s uncontrolled growth [8]. Essentially, the tumor cells divide faster than pre-
vasculature can provide them nutrients. These dividing cells require nutrients and oxygen 
for ATP synthesis, but when starved, express hypoxia inducible transcription factor 1 
(HIF-1) [11]. HIF-1 helps up-regulate glycolytic enzymes to help provide the cells with 
as much nutrients as possible [11] . This angiogenesis is driven by overexpression of 
factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), and platelet derived growth factor (PDGF) [8]. However, these newly formed 
blood vessels are not organized, and have abnormal structure and function [8]. Moreover, 
these vessels are leaky, which causes an increase in the interstitial fluid pressure, blood 
flow and thus oxygen distribution [8]. The uneven oxygen distribution also contributes to 
the hypoxic environment. The tumor microenvironment is considered extremely harsh for 
tumor infiltrating lymphocytes, and has shown to induce an “exhausted” phenotype in T-
cells [12] The low interstitial diffusion of therapeutics in solid tumors has also posed 
several challenges in treating cancers with nanoparticle based drug delivery systems [13]. 
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Figure 2 provides a comprehensive summary of all of the various types of cells and 
metabolic activities found in the tumor microenvironment. 
 
 
 
 
Figure 2: Schematic of the tumor microevinronment and various cell types present. Reproduced with 
permission from [14] Copyright© 2014, Elsevier Inc. 
	
 
 
 
In order to take advantage of the hypoxic tumor microenvironment, Yu et al reported the 
use of a hypoxia responsive functional group, 6-(2-nitroimidazole) hexylamine [15]. In 
hypoxic conditions, the hydrophobic nitro group converts to a hydrophilic amino group. 
This change in polarity induces swelling, which causes an increase in the release of their 
drug of interest. The mechanism of action can be seen in Figure 3 below. 
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Figure 3: The hypoxia sensitive mechanism of action of 6-(2-nitroimidazole) hexylamine (NIHA). 
Reproduced with permission from [15] Copyright© 2015, PNAS 
 
 
 
1.1.4 Current Immunotherapy Strategies 
Immunotherapy has arisen as a potential therapeutic to cancer due to its limited toxicity 
and use of the patient’s endogenous immune system [16]. Several different forms of 
immunotherapy exist such as Adoptive T-cell therapy, dendritic cell vaccines, antibodies 
targeted at disrupting check point blockades, and administration of cytokines to stimulate 
anti-tumor immunity [10, 16, 17]. Each method has shown promise in treating cancer in 
pre-clinical experiments and clinical trials, but others have struggled in evolving into 
viable, clinically available treatments. Adoptive T-cell therapy can include collecting a 
patient’s T-cells via apheresis, and expanding them ex vivo, or genetically re-engineering 
them to express a Chimeric Antigen Receptor [16]. Such forms of immunotherapy have 
shown high degrees of success in leukemia, but can struggle with solid tumor cancers and 
antigen negative escape mutations [16]. Cancer vaccines aim to use professional antigen 
presenting cells such as dendritic cells to prime T-cells to target cancer cells [17]. 
However, this approach is also antigen and epitope specific, making it susceptible to 
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escape mutations frequently seen in aggressive cancers such as melanoma  [17]. Cancer 
cells have been shown to avoid immunological responses by the patient’s own immune 
system via a series of checkpoint blockades [10]. By expressing ligands for various 
receptors on T-cells, cancer cells are able to induce T-cell exhaustion and initiate 
apoptotic pathways [10]. Checkpoint blockade inhibitors are capable of inhibiting such 
pathway initiations, but are subject to dosing limitations, and are thought to require a 
complimentary expansion of T-cells to adequately overcome the blockade [18]. One form 
of immunotherapy thought to have high potential in treating cancer was the 
administration of cytokines, such as Interleukin 12 (IL-12) in order to increase the 
number of tumor specific lymphocytes [19].  
 
1.2 Key Immunological Components in Immunotherapy  
1.2.1 T-cell Overview 
T-cells are a type of lymphocyte that play central role in cell-mediated immunity. T-cells 
mature in the thymus, and uniquely express a T-cell receptor (TCR) [20]. These cells are 
known to circulate through the blood and reside in secondary lymphoid organs awaiting 
activation [20]. Typically, T-cells are stimulated by professional antigen presenting cells 
such as dendritic cells, that present antigenic peptides to direct T-cell activity [20]. The 
affinity for various antigenic peptides is determined through T-cell clonal selection, and 
provides a vast possibility for T-cell specificity [20]. Once activated, the effector function 
of the T-cell depends largely on its phenotype [20]. CD8+ T-cells, or cytotoxic T-cells 
are responsible for direct of lysis of infected or malignant cells that bear the antigen [20]. 
CD4+ cells, or helper T-cells, are capable of producing cytokines that are directly toxic to 
affected cells, or to recruit and stimulate other lymphocytes [20]. Once the antigen can no 
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longer be detected, effector T-cells typically disappear, but are capable of establishing a 
memory T-cell phenotype that can survive up to several years [20]. Due to their robust 
functionality, and ability to overcome Human Leukocyte Antigen (HLA) restrictions, the 
enhancement of T-cell function has been thought to be a promising solution to cancer 
immunotherapy [16].    
  
1.2.2 Immune Check Point Blockade  
The Programmed Death-1 receptor and Cytotoxic T-lymphocyte antigen-4 (CTLA-4) are 
expressed on T-cells upon activation via their T-cell receptor complex (TCR) and CD28 
[10]. PD1 and CTLA-4 are responsible for down regulation of the immune system, and 
serve as key checkpoints in preventing the activation of T-cells [10].  These check points 
are natural, and have evolved as preventative mechanisms for autoimmune disease [10]. 
It has been well characterized that tumor infiltrating T-cells can be inhibited by Myeloid-
derived suppressor cells (MDSCs) found in the tumor microenvironment and tumor cells 
expressing PD-L1 and B7-1 which activate PD1 and CTLA-4, respectively [10]. The 
mechanism of tumor infiltrating T-cell infiltration is illustrated below in Figure 4. 
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Figure 4: The mechanisn of anti-PD1 and anti-CTLA-4 monoclonal antibodies in blocking checkpoints and 
enhancing T cell response to cancer cells. Reproduced with permission from [21] Copyright© 2013, Nature 
Publishing Group 
 
 
Immunotherapy aims to restore the function of these inhibited T-cells to recognize and 
eliminate cancerous cells. New drugs, such as Ipilimumab, an antibody against CTLA-4 , 
and Nivolumab, an antibody against PD1 have shown clinical efficacy in metastatic 
melanoma [2, 10, 22]. While these drugs have been successful in treating patients in 
clinical trials, appropriate dosing is crucial, as these drugs may induce autoimmune 
disease by allowing host specific lymphocytes to avoid elimination.  Moreover, these 
checkpoint blockades have been found to play significant roles in Melanoma, giving 
antiPD1 and antiCTLA-4 antibodies significant potential as therapeutics [23]. For 
example, the effects of antiPD-1 and stimulation of T-cells through the 4-1BB receptor 
has shown increased effector and memory T-cell function in the B16-F10 melanoma 
model [24]. 
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1.2.3 Interleukin-12 
IL-12 is a cytokine secreted by dendritic cells that acts on T-helper cells (CD4+) to 
induce differentiation into the Th1 phenotype [9]. The Th1 phenotype is known to play a 
large role in cell-mediated immunity, mainly be secreting cytokines, such as IFNγ [20]. 
IFNγ is a Type II Interferon that is known to have antitumor effects, can promote 
leukocyte homing and adhesion, and can also promote Natural Killer (NK) cell activity 
[25].  By administering IL-12, the amount of Th1 CD4+ cells secreting IFNγ would 
increase, and recruit an increased number of tumor specific endogenous cytotoxic T-cells 
(CD8+) to site of disease. The effects of different cytokines on CD4+ T-cell 
differentiation can be seen in Figure 5 below.  
 
 
 
 
Figure 5: The differentiation pathways for CD4+ T-cells under IL-12, IL-4, or IL-23 stimulation. 
Reproduced with permission from [26] Copyright© 2009, Nature Publishing Group 
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IL-12 has been thought to be a promising candidate due to its ability to stimulate both 
innate and adaptive immunity to mount a response against cancer cells [9]. Furthermore, 
IL-12 has been shown to help “coordinate” other biological actions with other cytokines 
such TNF-a, and IL-2 [27]. Moreover, IFNγ has shown to have anti-angiogenic 
properties, and reverses tumor evasion strategies by limiting myeloid derived suppressor 
cells [28] . Finally, IL-12 has shown to cause an upregulation of Vascular Cell Adhesion 
Molecule -1 (VCAM-1) in order to facilitate leukocyte recruitment [9].  IFNγ is also 
capable of initiating transcription of CXCL11 which is a chemokine that helps T-cell 
homing[29] [30]. The coordinated actions of IL-12 contributing to antitumor activity are 
shown in Figure 6 below.  
 
 
 
 
Figure 6: A summary of the effects of IL-12 on Anti-tumor immunity. Reproduced with permission from 
[9]. Unrestricted access according to Creative Commons Attribution License  
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While pre-clinical experiments using intra-peritoneal injections of IL-12 in mice showed 
a significant reduction in tumor burden and metastasis, the clinical trial involving the 
intravenous administration of IL-12 in humans was ultimately halted due to two patient 
deaths associated with IFNγ toxicity [31]. These patients suffered from rapid transient 
leukopenia, elevated liver transaminases (indicating apoptosis of hepatocytes), 
gastrointestinal toxicity, and/or liver dysfunction [31] . In supraphysiological levels in 
mice, IFNγ is known to cause emaciation, fluid filled intestines, splenic enlargement, 
skeletal and cardiac muscle necrosis, pleural effusions, lymphopenia, and 
hypoalbuminemia [31]. These effects can be strain dependent, and can include 
microscopic changes such as hepatic sinusoidal histiocytosis, reticuloenedothelial cell 
hyperplasia in the spleen and lymphoid tissues [31]. Despite these side effects, IL-12 has 
shown successes in preclinical models in B16-F10 melanoma mouse models [32].  
 
1.3 Drug Delivery Systems 
1.3.1 Current Strategies of Cytokine & Drug Delivery 
Several strategies have been proposed to avoid high serum levels of IL-12 and IFNγ, such 
as the transduction of tumor cells with a plasmid encoding IL-12, the conjugation of IL-
12 to an antibody, or using polymeric drug delivery systems for sustained release of the 
cytokine [33, 34]. These methods lack clinical relevance, and have several functional 
limitations. The transduction of tumor cells requires electroporation, and depends on the 
tumor to be easily accessible for success. Furthermore, transduction efficiency can be 
low, and secretion of the protein depends on tumor cell metabolism [35]. Covalent 
modification of IL-12 showed reduced toxicity, and was able to maintain most of the 
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biological activity of the protein [33]. However, this method also had poor tumor 
accumulation with its administration, and may require lager doses than necessary [33]. 
 
In an attempt to control dosing of potentially dangerous therapeutics such as 
chemotherapy drugs, polymeric micro/nanoparticles have been developed. These 
particles escape typical renal clearance mechanisms because of their size, and take 
advantage of the tumor’s high levels of angiogenesis and leaky vasculature to accumulate 
inside the tumor [4]. This phenomenon is known as the Enhanced Permeability and 
Retention (EPR) effect [3]. Nanoparticle drug delivery systems have also been proposed 
for the delivery of IL-12, but such systems rely solely on passive release during 
circulation. Drug release of these particles is primarily through erosion of the particle 
itself tumor [4]. Furthermore, they have low loading efficiency and capacities, and the 
particles are susceptible to opsonins during circulation tumor [4]. 
 
1.3.2 Nanogels 
Nanogels are hydrogel particles swollen with water composed of polymers and are either 
physically or chemically cross linked [36]. These particles are on the nano scale and are 
typically produced by an emulsion of an aqueous phase in an oil phase with the use of a 
surfactant [36]. A schematic of nanogels is illustrated in Figure 7 below.  
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Figure 7: Schematic of nanogel fabrication. A) Illustrates a water in oil emulsion and B) illustrates an oil in 
water emlusion. Both methods can be used to synthesize nanogels. Reproduced with permission from [36] 
Copyright© 2009, John Wiley and Sons. 
 
Nanogels have become increasingly more common in the design of drug delivery systems 
(DDS) due to their high loading capacity, hydrophilic nature, and tumor 
microenvironment-responsive potential [36]. Furthermore, these hydrogel-based delivery 
systems offer a large potential for adjustable properties that make them ideal for a variety 
of situations [37]. For example, simply adjusting the cross linking density of the nanogels 
can greatly alter the release profiles of the drug delivery system [36]. Moreover, the 
choice of polymer can affect degradation rate and half life of the nanogel [36]. Nanogels 
and nanoparticles can also be PEGylated, which can increase circulation time and 
modulate diffusion profiles [13].  Nanogels can be modified for environmental 
responsiveness in a multitude of ways [36]. Functional groups and residues can be added 
by taking advantage of functional groups found in the polymer backbone [36]. Cross 
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linking selection can also be important, as peptides resembling enzymatic substrates have 
been used to make nanogels and hydrogels enzymatically degradable [37].  
 
1.3.3 Hyaluronic Acid  
Hyaluronic acid (HA) is a component of the extracellular matrix (ECM) and synovial 
fluid [38]. HA is a type of glycosaminoglycan (GAGs), and has a large molecular weight 
that contributes to several different mechanical properties that make it a desirable 
biomaterial for biomaterials and tissue engineering applications [38]. Hyaluronic acid is a 
polymer composed of alternating D-glucuronic and N-acetyl-D-glucosamine residues 
[38]. Due to the presence of free hydroxyl and carbonyl groups, HA is capable of 
undergoing covalent modifications that can make it useful in forming drug delivery 
systems [15, 39]. Due to its hydrophilic nature, hyaluronic acid is able to increase the 
biocompatibility of other polymers and help reduce opsonin mediated immunogenicity 
[37]. The disaccharide monomer of hyaluronic acid is illustrated below in Figure 8 
 
 
 
Figure 8: The structure of Hyaluronic Acid. It is composed of D-glucuronic and N-acetyl-D-glucosamine 
residues. Reproduced with permission from [38] Copyright© 2006, Biotechnology Letters.  
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1.4 Purpose of Experimental Procedures & Aims  
The purpose of this study is to develop a nanogel drug delivery system that allows for the 
therapeutic delivery of Interleukin-12 as a form of immunotherapy to bolster anti-tumor 
immunity, while limiting systemic toxicity seen in intravenous administration of protein. 
Developing a polymeric drug delivery system can allow for high degree of 
customizability. Release of the protein of the can be modulated by altering specific 
properties of the nanogel such as cross linking density, and environmental 
responsiveness. By optimizing the nanogel platform, we can achieve a greater 
accumulation of therapeutic at the site of the tumor specifically, and maintain a sustained 
release of cytokine to optimize the differentiation of T-cells. This study also aims to 
characterize the size, diffusion profile, circulation time, bio distribution, and anti-tumor 
efficacy of the designed nanogels.  
 
Ultimately, the nanogels should be able to deliver the unmodified protein directly, and 
lack the functional limitations of previously proposed methods of cytokine delivery. This 
nanogel drug delivery system should have a high degree of clinical relevance by being 
administrated via intratumoral (IT) or intravenous (IV) injection.  
Briefly, the three specific aims of this study are: 
1) To develop a tumor microenvironment- responsive nanogel composed of 
modified hyaluronic acid containing a hypoxic sensitive moiety, and should 
maintain its susceptibility to enzymatic degradation.  
2) Show a reduction in tumor burden with a combinatory treatment of nanogel 
containing IL-12 and anti PD1.  
3) Recruit an increased number of tumor specific cytotoxic lymphocytes. 
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Chapter 2: ABET – Qualified Design Component 
2.1 Design Overview 
The proposed design is a polymeric drug delivery system on the nanoscale that is 
composed of modified hyaluronic acid and cross linked with dithiol PEG. The nanoscale 
of the particles allows for the avoidance of typical renal clearance mechanisms, and the 
hydrophilic nature of the hydrogel-like composition prevents detection via opsonins in 
the blood. Using the nanogel form allows for an encapsulation efficiency that is much 
higher than a double emulsion of a hydrophobic polymer-based system. The polymeric 
backbone of the nanogel is composed of hyaluronic acid and results in several 
advantages. Hyaluronic acid contains carboxyl and hydroxyl moieties that can be used to 
cross link the hydrogel and modify the polymer to conjugate various functional groups 
such as 6-(2-nitroimidazole) hexylamine (NIHA). This NIHA group provides the nanogel 
with the ability to release more drug in areas of increased hypoxia. The mechanism of 
action of this functional group is described below and was initially presented by Yu et al. 
Essentially, the functional group is normally a hydrophobic nitro group. However, in the 
absence of oxygen, the functional group is converted into an amino group via single 
electron reductases, which is largely hydrophilic. This change in polarity causes the 
nanogel to swell, increasing the release of cytokine. Another parameter that went into the 
selection of hyaluronic acid was its ability to be enzymatically degraded by 
hyaluronidase. As previously mentioned, the degree of hyaluronidase in the tumor 
microenvironment can help actively degrade the nanogel specifically at the tumor site. 
Hyaluronic acid also has a longer half life and longer circulation time than other 
polymers such as Dextran, that were originally proposed for this thesis study. 
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Furthermore, the hydrophobic nature of the attached moieties can help limit unwanted 
passive diffusion in circulation.  
 
Interleukin-12 was chosen as a cytokine for this study due to its previous use in treating 
melanoma. Interleukein-12 was thought to promote the amount of tumor-specific 
cytotoxic lymphocytes through its ability to skew CD4+ T-cell differentiation into the Th1 
phenotype. The Th1 phenotype is known to stimulate cell-mediated immunity through the 
secretion of IFNγ and other cytokines. The nanogel system provides an opportunity to 
illustrate the sustained release of a potentially dangerous therapeutic, and may address a 
crucial limitation in an otherwise potent molecule. Surface modifications such as 
PEGylation were considered, but were deemed unnecessary because of the hydrophilic 
nature of the nanogels. Furthermore, PEGylating the nanogels could hinder release of IL-
12, which is unwanted especially if the nanogel has successfully accumulated in the 
tumor.  
 
2.2 Design Comparison and Analysis  
In order to best compare the design options available, a SWOT diagram, a 
decision matrix, and a systems block diagram were used to analyze the nanogels. 
These design tools illustrate the strengths and weaknesses of each specification of 
the potential designs, and helped determine an overall design for the proposed 
IL12 delivery system. 
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2.3 SWOT Analysis  
Table 1 illustrates the SWOT analysis of the tumor micro-environment responsive 
nanogel. This analysis shows significant opportunities to overcome a major 
challenge in cytokine based immunotherapies. Increased accumulation of the 
therapeutic to the tumor prevents the risk of toxicity, and increased tumor burden 
reduction. Furthermore, this analysis highlights the potential of this therapeutic to 
be combined with currently existing immunotherapies, such as Chimeric Antigen 
Receptors. While IL-12 was encapsulated in this particular study, other cytokines 
and chemokines may be encapsulated to stimulate and attract other cells of the 
immune system. The risk of accumulation in the liver is highlighted, and potential 
constraints of circulation time on dosing have been taken into consideration. 
However, these limitations can be partially overcome with optimization of certain 
nanogel parameters such as diffusion and circulation time. Overall, the proposed 
drug delivery system platform provides several benefits to improve cancer therapy 
with understood risks and limitations. 
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Table 1: SWOT Analysis of the Tumor Micro Environment-Responsive Nanogel 
 
Helpful Harmful 
In
te
rn
al
 O
ri
gi
n 
Strengths 
Allow for localized and controlled 
delivery of a potentially systemically 
toxic cytokine 
Weaknesses 
Limits the dose to the maximum 
loading capacity and minimum 
circulation time of the nanogels. 
 Opportunities: 
Can significantly increase the 
efficacy of novel immunotherapies 
to treat solid tumor cancers 
Threats:  
High accumulation and release in the 
liver may help promote IFNγ 
toxicity. 
 
 
 
2.4 Decision Matrix 
A decision matrix was used to formally compare the tumor microenvironment-
responsive drug delivery system, a passive release based drug delivery system, the 
transfection of tumors with IL-12 encoding plasmid, and covalent modification of 
the IL12. The options were compared for translation features such as ease of use 
and potential failure, as well cancer specific characteristics. As seen below in 
Table 2 the tumor microenvironment-responsive nanogel DDS ranks the highest. 
It is of note however, that the passive released based DDS is ranked just slightly 
lower. This indicates the advantages gained by using a nanogel based drug 
delivery system as opposed to relying on the transduction efficiency and 
E
xt
er
na
l O
ri
gi
n	
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metabolism of cancer cells, and injecting a covalently modified protein 
intravenously. The transfection of tumor cells with plasmid coding for IL-12 is 
greatly limited by its ease of use, as most tumors may not be close enough to the 
surface for electroporation. However, the secretion of the protein is limited to the 
tumor microenvironment.  The administration of a modified version of IL-12 is 
the least favorable option as there is a large risk of serum levels of IFNγ rising to 
supraphysiological levels. Furthermore, the covalent modification potentially 
compromises biological activity of the protein, and has inferior tumor 
accumulation compared to the nanogel DDS. The potential for controlling the 
release specifically in the tumor microenvironment separates the proposed 
nanogel as the superior design.  
 
 
Table 2: Decision Matrix of Various Delivery Methods of IL-12 
 
 
 
 
Options Tumor Microenvironment- 
Responsive 
Nanogel DDS 
Passive 
Release 
Nanogel 
DDS 
Transfection of 
Tumor Cells 
with Plasmid 
Covalent 
Modification 
of Protein Criteria 
Tumor Specific Release 5 3 2 2 
Tumor Accumulation 5 5 5 2 
Biological Activity 5 5 5 4 
Dosing Efficiency 4 4 2 3 
Ease of Use 3 3 2 4 
Potential Failure 3 3 4 2 
Score 25 23 20 17 
Rank 1 2 3 4 
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2.5 Systems Block Diagram 
The mechanism of action of the tumor microenvironment-responsive nanogel 
DDS is illustrated by the systems block diagram seen in Figure 9 below. Of note, 
the diagram highlights the accumulation of the therapeutic to the tumor 
microenvironment, the responsive release of IL-12, the differentiation of the 
CD4+ T-cells, and the recruitment of tumor specific lymphocytes for the 
destruction of tumor cells.  
 
 
 
 
Figure 9: Systems block diagram describing the mechanism of action for the proposed nanogel. 
 
 
 
2.6 Design Criteria  
In order to properly design the nanogel, several design criteria were established to 
be met. The criteria are listed below with supporting rationale.  
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Nanogel Size: The nanogel are to have a mean diameter no greater than 150 nm, 
and a mean Polydispersity index (PDI) no greater than 0.3 By achieving this size 
and distribution, the nanogels may adequately clear typical renal clearance 
mechanisms. 
Encapsulation Efficiency: The nanogel’s encapsulation efficiency should be 
enough such that a biologically relevant dose can be delivered. It should also be 
as high as possible to prevents waste and loss of expensive cytokine. 
Cytokine Release: The cytokine released from the nanogel must maintain its 
biological activity and have at least an equivalent differentiation capacity as free 
recombinant human IL-12 in a culture of CD4+ T-cells at 10 ng/mL. This 
approximately equates to at least 72 ng in 4 days. 
Circulation Time: The circulation time of the nanogels must be at least the 
amount of time required for the majority of the nanogel to accumulate into the 
tumor. 
Bio Distribution: The bio distribution of the nanogel must follow several criteria; 
The nanogel is to have zero accumulation in the brain and heart. The nanogel 
must also have the greatest accumulation in the tumor.  
 
Chapter 3: Materials and Methods 
3.1 Polymer Synthesis 
3.1.1 Synthesis of methacrylated-HA (MAHA) 
0.8 g HA (33 kDa, 2.08 mmol carboxylic acid groups) was dissolved in 40 mL of 
distilled water (DI water). A five molar excess (relative to the carboxylic acid groups in 
HA) of methacrylic anhydride (MA, 10.4 mmol, 1.6 g) was added dropwise to the 
solution at 0o C. The reaction pH was adjusted to 8-9 by the addition of 4M NaOH. The 
	 23 
reaction was continued overnight at room temperature.  After 24 hours, the product was 
precipitated in cold ethanol, washed three times with ethanol, and dried under a vacuum. 
The product MAHA was dissolved in DI water, and the solution was dialyzed (dialysis 
tube: molecular weight cut-off 10,000) against DI water for 48 hours. Purified MAHA 
was lyophilized and stored desiccated at 4o C until use.  
 
3.1.2 Synthesis of 6-(2-nitroimidazole) hexylamine (NIHA) 
2-nitroimidazole (NI) (0.15 g, 1.3 mmol) was dissolved in 3 mL dimethyl fluoride 
(DMF), to which K2CO3 (0.28 g, 2.0 mmol) was added. 6-(Boc-amino) hexyl bromide 
(0.39 g, 1.4 mmol) was then added dropwise and stirred at 40o C overnight. The reaction 
mixture was filtered and washed with methanol. The residual solvent was evaporated 
using a rotary evaporator (90oC). The solid obtained was suspended in water and 
extracted with ethyl acetate three times. The organic layer was separated, dried over 
sodium sulfate overnight, and concentrated to obtain the product 6-(2-nitroimidazole) 
hexyl-boc-amine (product 2 in Fig.10). The resulting product was dissolved in methanol 
and cooled to 0o C, to which 5 mL of 1.25 M HCl in methanol was added and stirred at 
room temperature for 24 hours. The solvent was removed from the reaction mixture using 
a rotary evaporator. The crude solid was recrystallized from ethanol to obtain 6-(2-
nitroimidazole) hexylamine (NIHA, product 3 in Figure 10). 
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Figure 10: Synthetic Route for 6-(2-nitroimidazole) hexylamine (NIHA) 
 
 
 
3.1.3 Synthesis of NIHA-MAHA 
0.15 g MAHA was dissolved in a mixed solution of H2O and DMSO (3 mL H2O/12 mL 
DMSO). Once dissolved, 58 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and 35 mg N-Hydroxysuccinimide (NHS) were added, and stirred for 15 min at 
room temperature. Next, 0.16 mL 6-(2-nitroimidazole) hexylamine in DMF solution (100 
mg/mL, 16 mg in 0.16 mL DMF) was added to the mixture and allowed to react at room 
temperature for 24 hours. The reaction solution was thoroughly dialyzed against a 1:1 
mixture of DI water and methanol for 1 day, and DI water for 2 days. Purified NIHA-
MAHA was lyophilized and stored desiccated at 4o C until use. 
 
3.2 Fabrication of Nanogels  
3.2.1 Inverse Micro Emulsion 
The NIHA-HAMA solution, dithiolPEG [molecular weight 1000] and protein were added 
to an Eppendorf tube and homogenized with a vortex mixer. The resulting water phase 
was added to the organic phase and surfactant. The heterogeneous mixture was mixed by 
vortex mixer for 1 minute to perform the micro emulsion. After 12 hours at room 
temperature, the cross-linked nanogels were precipitated by the addition of excess 
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organic phase. The heterogeneous mixture was centrifuged for 1 min at 2000 rpm speed. 
After the supernatant was removed, organic phase was added and the same procedure was 
repeated 3 times to remove the surfactant. The precipitated nanogels were finally dried 
under vacuum, and re-suspended in 1 mL of PBS.  
 
3.2.2 Purification 
The nanogel solution was washed using 10 mL of the organic phase again (spun at 4,400 
rpm for 5 minutes) at least 4 times. The final nanogel solution was filtered (0.45 µm) and 
stored at 4o C before further use.   
 
3.3 Characterization of Nanogel Size and Distribution 
The size and polydisperisty index of the nanoparticles was determined by using a 
provided Zetasizer. The particles were read with 630 nm and were measured using a 
standard operating procedure that averaged 12 different measurements.  
 
3.4 Release Studies 
3.4.1 Bovine Serum Albumin (BSA) Release 
The sample (n = 3) was filtered with a 300 kDa filter at 10,000 RPM to remove un-
encapsulated free protein. The filter was washed twice with buffer. The volume was 
adjusted 0.5 mL then incubated at 37 o C with a gentle shake. At various time points, the 
same filter was used to remove released FITC-BSA, and the volume removed was 
replaced. The volume of BSA released was noted, added to a 96 well plate (200 uL) and 
the intensity was measured with a Tecan at 485 nm. The encapsulation efficiency was 
calculated by subtracting the amount of free protein washed away from the theoretical 
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100% amount of protein encapsulated. This was then divided by the 100% amount of 
protein encapsulated and multiplied by 100. 
3.4.2 Interleukin- 12 Release (Passive) 
The release of passive IL-12 (n = 2) was performed with same protocol as section 3.4.1. 
The amount of IL-12 released was quantified using an IL-12 Enzyme Linked 
Immunosorbent Assay (ELISA). The concentrations were interpolated using a standard 
curve of known concentrations of IL-12. 
 
3.4.3  antiPD1 Release  (Passive) 
The release of passive FITC-antiPD1 (n = 3) was performed with same protocol as 
section 3.4.1. The amount of antiPD1 released was determined with a TECAN at 485 nm. 
 
3.4.4 Interleukin-12 Release (Enzymatic Degradation) 
The nanogel sample (n = 2) was diluted 3 times to 0.25 mg/mL. The sample was then 
filtered with a 0.45 um filter to remove any bacteria. The pH of the solution was adjusted 
to 6.5 using 1.25 M HCl. Two samples were run in parallel. Hyaluronidase was added at 
500units/mL. The samples were incubated at 37 degrees C and time points were collected 
at 0,2,4, 12 and 24 hours. At 12 hours, Hyaluronidase was added again at 500 units/mL.  
The control group had an equal volume of PBS added. The quantification of the release 
was performed according to the protocols of sections 3.4.1 and 3.4.2. The size and 
polydispersity index were monitored at each time point using a Zetasizer at 630 nm.  
 
3.5 Circulation Time  
Alexa fluor 647-labelled nanogel were fabricated according to the protocol in section 
3.2.1 and 3.2.2. The nanogel sample was intravenously injected in BALB/c mice bearing 
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a 4T1 tumor through the tail vein. 10 µL of blood was collected at various time points 
over a 24-hour period. The fluorescent intensity of the blood samples was evaluated with 
a Tecan Infinite m200 Fluorescent Plate Reader at 665 nm with an excitation wavelength 
at 635 nm.  
 
3.6 Bio distribution of Nanogels 
Similarly, prepared Alexa fluor 647-labeleld nanogels were tested for biodistribution in 
4T1 tumor bearing mice. Saline and nanogel were injected intravenously through the tail 
vein. After 24 hours, the mice were sacrificed, and the brain, heart, lung, liver, spleen, 
kidney and tumor were harvested. The organs were then imaged using an In Vivo 
Imaging System (IVIS).  
 
3.7 Biological Activity Assay 
3.7.1 T-cell Activation and Culture 
CD4+ T-cells from a donor were obtained from the Human Immunology Core at the 
University of Pennsylvania. Culture of CD4+ T-cells was initiated at 1 million cells/mL 
and maintained at 800,000 cells/mL. Cells were cultured in RPMI 1640 (+L-Glutamine) 
1% HEPES, 1% Penn Strep, and 10% FBS. T-cells were activated with anti CD3 and anti 
CD28 dynabeads at a ratio of 3 beads/cell. T-cells were cultured for 7-9 days, and were 
counted and assessed for size with a Coulter Counter. T-cell viability was assessed every 
other day with a hemocytometer and Trypan Blue. The cells were treated with nanogels, 
nothing, or recombinant human IL-12 on days 1 and 3. The nanogels were added at 10% 
of the culture volume in PBS at 0.2 mg/mL, 0.067 mg/mL and 0.02 mg/mL. Recombinant 
human IL-12 was added at 10 ng per each mL of culture volume. The viability was 
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confirmed using Flow Cytometry and Live/Dead Aqua staining. A fixable BV510 nm 
isotype was used as a control. 
3.7.2 Re-Stimulation  
On day 8 of culture, the dynabeads were magnetically removed from the cells, and the 
cells were concentrated to 1 million cells/mL. The cells were then pharmacologically 
restimulated with PMA and Ionomycin. The cells were then treated with Golgi Block, 
and incubated for 6 hours.  
 
3.7.3 Surface and Intracellular Staining  
Following the incubation, the cells were fixed, permeabilized, and stained with 
monoclonal antibodies for CD4, Live/Dead Aqua, IFNγ, and CD8. Flow cytometry data 
was analyzed using FlowJo. 
 
3.7.4 Flow Cytometry 
Flow cytometry was performed at Penn Flow Cytometry and Cell Sorting Center with an 
LSR flow cytometer BD Biosciences. 10,000 events were collected, and mouse IgG 
isotypes were used as controls for each fluorophore used.  
 
3.8 Anti-Tumor Experiment in vivo 
B16-F10 melanoma tumor cells were established on C57BL/6J mice. Twelve days after 
tumor inoculation, mice in three groups received saline, 100 µg of anti-PD1 via 
intraperitoneal injection, and 2.5 µg  IL-12 encapsulated in a nanogel sample via 
intratumoral injection in combination with anti-PD1, respectively. Tumor size was 
monitored via caliper measurement. A two way t-test in excel was used to assess 
statistically significant differences between groups with α = 0.05. 
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3.9 CTL Assay   
At day 17, the mice were sacrificed and their spleens were harvested. Isolated 
splenocytes were restimulated with mitomycin C-treated B16-F10 melanoma cells for 5 
days and were collected for the CytoTox 96 Non-Radioactive Cytotoxicity assay. This 
assay was performed according to the provided protocol. Briefly, a 96 well was plate 
containing 5000 tumor cells in culture medium was set up, and the splenocytes were 
added at different effector to target ratios in a 200 µL volumes. The cells were incubated 
for 4 hours. 50 µL aliquots of the supernatant was collected after the incubation, and 
transferred to a fresh 96-well plate. 50 µL of the CyoTox 96 Reagent was added to each 
well, covered with aluminum foil to protect the samples from light, and incubated at 30 
minutes at room temperature. 50 µL of the stop solution was added to each well, and the 
absorbance was recorded at 490 nm within 1 hour of adding the stop solution. A two way 
t-test in excel was used to assess statistically significant differences between groups with 
α = 0.05. 
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Chapter 4: Results 
4.1.1 Particle Size & PDI 
Table 3 indicates the mean diameter and polydispersity index (PDI) of the nanogels. The 
mean diameter of the nanogels was 120 nm with a standard deviation of 13.089 nm. 
 
 
Table 3: The mean size and standard deviation of the nanogel diameter and PDI 
 Mean (nm) Std Dev 
Diameter 120 13.089 
PDI 0.268 0.048 
 
 
4.1.2 Cytotoxicity  
Table 4 indicates the percent viability of the T-cell culture at 24 and 72 hours after being 
treated with either PBS or 0.2 mg/mL of empty nanogel at 10% of the culture volume. 
 
 
Table 4: The percentage of viable cells 24 and 72 hours post exposure to the empty nanogel 
 
PBS 
Empty 
Nanogel 
% Alive - 24 hours 94 91 
% Alive - 72 hours 87 89 
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4.1.3 Release Profile 
 
 
 
Figure 11: Protein release from nanogels. A) The passive release profile of BSA over the course of 6.25 
days. (Encapsulation Efficiency of 47% with input of 100 µg) B) The passive and enzyme-mediated release 
of IL-12 over the course of 4 days. (Encapsulation Efficiency of 73% with input of 1 µg)  C) The passive 
release of antiPD1 over the course of 5 days. (Encapsulation Efficiency of 32% with input of 100 µg). 
 
 
 
Figure 11 Illustrate the release profile of the designed Nanogel. Figure 11-A illustrates 
the release profile with Bovine Serum Albumin and Figure 11-B illustrates the passive 
release and enzyme mediated release of IL12. Figure 11-A shows there was quick release 
of BSA within the first 24 hours of the release study, followed by a much more gradual 
release over the next 5 days. Figure 11-B shows that hyaluronidase was able to increase 
the release of IL12 within the first 3 days of the release study. Ultimately, the two groups 
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released approximately the same amount of cytokine. There was no significant difference 
between the release of the sample with the enzyme and the control, with p =0.55. The 
sample with the enzyme released 108.88 ng after 100 hours, while the control sample 
released the 100.59 ng in the same time frame. Figure 11-C shows that the nanogel is 
capable of releasing 40% of the encapsulated antiPD1 over the course of 5 days. 
 
4.1.4 Circulation Time and Biodistribution 
 
 
 
 
 
 
 
 
 
	
 
 
 
 
 
Figure 12: Nanogel blood circulation and biodistribution. A) The relative intensity of the nanogel in the 
plasma post-injection. B) IVIS fluoresence image of tissues 24 h post injection, showing nanogel 
accumulation in tumors. From left to right: brain, heart, lung, liver, spleen, kidney, and tumor.  
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Figure 12 illustrates the half life and biodistribution of the hyaluronic acid  nanogel drug 
delivery system. Figure 12-A illustrates the relative intensity of the nanogel in peripheral 
blood at various time points post injection. The nanogel intensity illustrated an initial 
sharp reduction after the first hour, followed by a more gradual drop in intensity over 
time for the rest of the study. By fitting the graph from Figure 12- A into a two 
compartment model, the calculated half lives were 0.2 hours, and 7.3 hours, respectively.  
Figure 12-B illustrates the biodistribution of the fluorescently labeled nanogel when 
injected intravenously through the tail vein. The liver and tumor resulted in the largest 
and second largest uptake of the nanogel, respectively. The kidneys had the next largest 
uptake, followed by the lungs and spleen. The heart and brain had zero measurable 
uptake of the nanogel.  
 
4.2 Biological Activity & Differentiation Capacity  
4.2.1 Differentiation Capacity 
 
 
 
 
Figure 13: IFN-γ production of CD4+ T cells under IL-12 encapsulated nanogels.  
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Figure-13. Illustrates the flow cytometry results of the assay performed to verify the 
emulsion process of the nanogel did not alter the biological activity. The peaks of 
positive events represent IFNγ secreting cells, and can be therefore classified as T-cells of 
the Th1 phenotype.  As seen in the figure below, the nanogel with encapsulated IL-12 
resulted in 78.5% of the CD4+ cells differentiating into the desired Th1 phenotype. The 
free IL-12 resulted in 48.3% of the cells being differentiated, and the control groups were 
untreated completely or treated with an empty nanogel. The peaks on the left illustrate the 
unstimulated T-cells. There was no significant difference between these groups, 
indicating that there was no release of cytokine in the absence of pharmacological 
stimulation.  
 
4.2.2 Population Doublings & Cell Size 
 
 
 
 
Figure 14: The population doublings of the nanogel treated CD4+ T-cells throughout their culture. 
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The population doublings of the T-cells of each group were monitored each time the cells 
were ready for passage. Figure 14 indicates that the T-cells treated with the empty 
nanogel and the non-treatment group had a slightly larger amount of population 
doublings. The empty nanogel at 0.067 mg/mL had the highest number of population 
doublings with 4.296. The group treated with IL12 carrying nanogels at 0.067 mg/mL 
had the lowest number of population doublings with 3.127. This indicates a potential 
difference of up to 1 single population doubling. 
 
 
 
 
Figure 15: The size of the nanogel treated CD4+ T-cells throughout their culture. 
 
 
The size of the T-cells was also assessed over the course of the T-cell culture. As seen in 
Figure 15, there is clear separation between the cells were that stimulated by either the 
eluted IL-12 or the nanogel containing IL-12 directly. The group treated with the 0.2 
mg/mL of nanogel containing IL-12 had the largest volume with 676 fL, while the non 
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treated group had a size of 406 fL. The group treated with the empty nanogel had a size 
of 498 fL and the free IL-12 at 10 ng/mL group had a size of 465 fL. 
 
4.3 In Vivo Experiment  
4.3.1 Anti-Tumor Experiment  
 
 
 
Figure 16: In vivo tumor growth inhibition curves for B16-F10 tumor bearing mice that were treated with 
either anti-PD1 antibody, a combination of anti-PD1 antibody and IL-12 encapsulated nanogels, or 
untreated.  
 
 
 
The anti-tumor efficacy of the hyaluronic acid nanogel was determined by treating mice 
inoculated with B16-F10 melanoma tumors. The mice were treated twelve days after the 
tumors were established with a mean size 262.2 +/- 103.9 mm3. As seen in Figure 16, the 
group of mice treated with nanogel encapsulated with IL12 and the administration of 
antiPD1 had the smallest tumor size at day 17 with a size of 441.58 +/-213.37. The group 
that received only antiPD1 had the largest mean size of tumor, but also had the largest 
standard deviation. The difference in tumor size between the control group and the 
combinatorial treatment was less but not statistically significant with p = 0.49. 
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4.3.2 CTL Assay 
 
 
 
 
 
Figure 17: The percentage of lysed B16-F10 melanoma cells when co-cultured with splenocytes at different 
Effector (splenocytes) to Target Ratios (cancer cells) (E:T). The splenocytes were harvested from B16-F10 
tumor bearing mice that have been treated with either anti-PD-1 antibody, the combination of anti-PD1 
antibody and IL-12 encapsulated nanogels or untreated.  
	
	
A cytotoxic T-lymphocyte (CTL) assay was performed to determine the number of tumor 
specific T-cells. At an effector to target (ET) ratio of 100:1, the T-cells harvested from 
the sacrificed mice were able to lyse 23% of the tumor cells. This was the highest 
percentage of tumor cells that was lysed, and was significantly higher than the antiPD1 
group, with p = 0.02. It is of note that there was a statistical difference at the ET ratio of 
50:1 as well, with p = 0.04. The combination treatment group had a higher percent lysis 
of tumor cells at every E: T ratio. There was no significant difference between the PD1 
treatment and the control group. The % lysis vs the ET Ratio of T-cells is seen in Figure 
17. 
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Chapter 5: Discussion 
5.1 Nanogel Characterization  
5.1.1 Particle Size, PDI, & Cytotoxicity  
The size of the particles reported here is consistent with other nanovehicles previously 
published, and are small enough to escape typical renal clearance mechanism [36, 39]. 
The mean polydispersity index of particles encapsulated with IL-12 was 0.268, indicating 
the distribution of the particle size stays within an approximate range of 50 nm to 300 
nm.  The potential cytoxicity of the nanogels themselves was considered in this study. 
The results shown in Table 4 illustrate no significant difference in the cell viability 
between the control and nanogel groups. These results are consistent with hyaluronic 
acid’s low immunogenicity and cytotoxicity [38]. However, these results illustrate that no 
side effects from the nanogel themselves are expected. 
 
5.1.2 Release Profiles 
Release characterization studies of the nanogel illustrate that the nanogel is capable of 
maintaining a sustained release of cytokine in the absence of enzymatic activity. In the 
presence of hyaluronidase, the enzyme facilitates a slightly faster initial release, but 
ultimately yields a similar sustained release compared to the passive sample. The lack of 
significant differences between the release profiles could be attributed to the significant 
modifications made to the polymeric backbone of hyaluronic acid. Hyaluronidase 
typically uses the monomeric disaccharide as an active site for its degradation of HA. 
However, covalent modifications were made that alter the carboxyl group and hydroxyl 
groups of the HA to add the hypoxic responsive functional group and cross link the 
nanogels, respectively. It is plausible that the enzyme loses its ability to degrade HA 
because of the modifications made to the backbone that interacts with the enzyme active 
	 39 
site. Despite the lack of significant results shown here, the degree of substitution of these 
covalent modifications can be adjusted by simply altering the molar ratios during the 
polymer synthesis process. Thus, the degree of enzymatic responsiveness can be further 
optimized if needed. These results indicate the gel can be synthesized to release more 
protein in areas of increased hyaluronidase (and thus tumor burden), without significantly 
altering the sustained release profile.  The sustained release of BSA is promising, as it 
indicates the nanogel releases proteins slowly. The nanogel was only capable of releasing 
40% of the encapsulated antiPD1. This can be attributed to the high molecular weight of 
the anitPD1 antibody (153 kDa), which is approximately 3 times that of IL-12 and BSA. 
The high cross linking density of the nanogel, and conjugated hydrophobic moieties may 
also contribute to the slow protein release.  The encapsulation efficiency of the nanogel 
was sufficient for encapsulating enough protein to provide a biologically relevant dose.  
 
5.1.3 Circulation Time & Biodistribution 
The half life of the nanogel was calculated using a two compartment model. 
Consequently, the fast half life of the nanogels was 0.18 hours, and the slow half life of 
the nanogel was 7.3 hours. The initial decrease in relative intensity could be a function of 
the hydrophobic nature of the modifications made to the hyaluronic acid. The 
hydrophobic hypoxic responsive group may actually increase the nanogel’s susceptibility 
to circulating opsonins in the blood, and thus generate a greater immune response in 
instances of higher concentrations – such as the initial injection. This too can be adjusted 
by further optimization of the degree of substitution during polymer synthesis. Surface 
modifications such as PEGylation can also be considered, but must be carefully applied 
in the context of this project due to the enzyme’s active site specificity, and potential 
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inhibition of the passive release of cytokine from the drug delivery system. The slow half 
life of this nanogel is comparable to other reported half lives of hyaluronic acid based 
drug delivery systems, and should allow for adequate tumor accumulation if administered 
intravenously [39]. The biodistribution study of this nanogel indicates that the nanogel 
most greatly accumulates in the liver and the tumor. The large uptake by the liver may be 
problematic as the IFNγ toxicity that results from supraphysiological levels of IL-12 can 
have toxic effects on the liver such as hypoalbuminemia and elevated transaminase 
levels.  However, the high levels of accumulation in the tumor are promising. The 
accumulation of the nanogel in the tumor may be further increased by diverting or 
preventing accumulation in the liver. Several strategies have been proposed to redirect 
accumulation such as PEGylation. Kupffer cells are macrophages located in the liver that 
have been attributed to reduced nanoparticle accumulation in tumors and other desired 
tissues [40].  
 
5.2 Biological Activity & Differentiation Capacity  
5.2.1 Differentiation Assay  
 
The biological activity results illustrate that the nanogel maintains the biological activity 
of the encapsulated IL-12. Interestingly, the amount of Th1 cells in the nanogel group was 
greater than the free IL-12 group. This could be attributed to the sustained release of the 
drug delivery system, and illustrates that the same dose administered gradually over time 
can provide the same, if not greater results than a single dose. By performing the 
experiment specifically with IL-12 and CD4+ cells, the ability to force the differentiation 
with the nanogel has been shown here. Moreover, this indicates great promise for the 
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emulsion process used to synthesize these nanogels, as different polymers can be used to 
create a variety of drug delivery systems with biologically active proteins.  
 
5.2.2 Population Doublings & Cell Size 
The characterization of the population doublings and size of the T-cells cultures sheds 
light on the effects of IL-12, and the benefits of a sustained release. As seen in Figure 14, 
the cells that were not stimulated with the nanogel had approximately 4 population 
doublings, while the cells treated with the nanogel had approximately 3 population 
doublings. This difference may be explained by Figure 15, which illustrates the cells 
stimulated with the nanogels containing IL-12 maintained a larger size throughout the 
culture. The figure shows a clear separation, and can be attributed to the increased 
amount Th1 cells present in the culture. Each group of cells began the culture with an 
increased size, due to the stimulation of the antiCD3 and antiCD28 beads. However, T-
cells typically began to decrease in their volume as their metabolic activity declines. The 
increased size of the cells treated with the nanogel are an indication that the differentiated 
T-cells are secreting cytokine and maintaining their active metabolic states. It is theorized 
that the differentiated cells reduce proliferation rates in order to maintain this high cost 
metabolism that secretes IFNγ and other pro inflammatory cytokines. Interestingly, the 
size of the group treated with recombinant human IL-12 was similar in size to the cells 
treated with empty nanogel. This may be a function of the sustained release provided by 
the nanogels, and illustrates the sustained release may stimulate cells more efficiently.  
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5.3 In Vivo Experiment  
5.3.1 Anti-tumor Experiment  
The results of this pilot vivo experiment indicate this drug delivery system has potential 
for anti tumor efficacy. While not significant, the combinatorial group had the lowest 
tumor burden at day 17. The group of mice (n=2) receiving the antiPD1 had the largest 
average tumor size, but also had the largest standard deviation. One mouse had a tumor 
size of 2054 mm3 while the other mouse in the group had a tumor size of 454 mm3-which 
is quite comparable to the combinatorial groups mean of 441.59 mm3.  These results 
could imply several different possibilities, and would need to be repeated for more 
accurate conclusions. The combinatorial treatment group had a much smaller standard 
deviation than the antiPD1 group. Antitumor efficacy has been shown in antiPD1 mouse 
studies using the B16-F10 melanoma model with varying consistency [6, 41] Assuming 
the intraperitoneal injection was successfully executed, the outlier could be a function of 
the limitations of the antiPD1 therapeutic, or a result of a particularly aggressive tumor. 
B16-F10 melanoma tumors were established and allowed to grow until they reached 100 
mm3 (day (12) While some antitumor experiments have allowed the tumors to reach this 
size, some studies began treating the mice at 4 days post inoculation with the tumor [27, 
32]. This earlier treatment is likely due to the aggressive nature of this model, and could 
be a critical point in the tumor growth that may affect the tumors sensitivity to treatment. 
Furthermore, the combinatorial treatment of IL-12 and antiPD1 is thought to 
simultaneously inhibit the induction of the apoptotic pathway in T-cells and increase 
cytokine secretion to increase the amount of T-cell recruitment in order to overpower the 
tumor’s escape mechanisms. The outlier in the antiPD1 group could also simply be an 
indication that the antiPD1 therapeutic was incapable of limiting tumor burden without 
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the cytokine induced expansion and recruitment of additional T-cells. It is of note 
however, that the non treatment group had a mean size of 837 mm3, which is 
approximately twice the size of the combinatorial treatment group. Furthermore, this pilot 
study was performed by injecting the therapeutic intratumorally. While these result shows 
potential for antitumor efficacy, the method of injection is a major factor, and one that 
requires further experimentation to elucidate. By injecting the therapeutic intravenously, 
the clinical relevancy of this design drastically increases, but given the increase of 
laparoscopic surgeries performed, intratumorally injecting the therapeutic may not be out 
of the question. If further experiments are capable of illustrating the significance of the 
sustained release of IL-12, the disadvantage of liver accumulation can be accepted. 
Optimization of the dose may further substantiate the antitumor results.  
 
5.3.2 CTL Assay 
The results of the CTL assay are perhaps the most promising results of this study. These 
results indicated a statistically significant difference in the amount of tumor specific 
cytotoxic T-lymphocytes, with n = 3, p = 0.02. In this experiment, there is no significant 
difference between the antiPD1 treatment group and the control group. These results 
could indicate the advantage of a combinatorial approach to immunotherapy. While 
checkpoint blockades may limit the cytotoxic lymphocyte hypofunction induced by 
tumor cells expressing particular ligands, the secreted IFNγ may provide the necessary 
vigorous proliferation cues necessary to drive T-cell selection in favor of tumor 
specificity.  
Due to limited resources and the investigative nature of this study, the number of mice in 
each group was small, and this experiment should be repeated for more conclusive data. 
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Moreover, there was not enough mice to include a group with just IL-12. The ulcerative 
nature of these tumors required an amendment to the animal protocol at the end of this 
study, and resulted in the termination of the experiment on day 17. A secondary dose of 
nanogels were scheduled to have been prepared on day 19, which may have further 
clarified the differences between treatment groups. The groups were selected with the 
following logic: a non-treated group was necessary to establish a baseline control tumor 
growth curve. The antiPD1 group was selected because it is currently a therapeutic found 
in preclinical and clinical trials, with known effects. A group that was purely IL-12 was 
not used to maximize the size of n for the combinatorial treatment group. A clinical trial 
has been recently announced involving the co-delivery of these two therapeutics [42]. 
However, this study utilizes electroporation and a plasmid encoding for IL-12 as the 
source of cytokine delivery [42]. This greatly limits the clinical translatability of their 
approach, and the secretion of the protein largely depends on a transfection process that is 
known to have low yield, and the metabolism of mutated cells. Though treatment with 
IL-12 has shown to have antitumor potential, when used alone, tumor burden reduction 
data is variable and can cause adverse side effects [9, 27]. In an attempt to provide a 
highly robust drug delivery system with antitumor efficacy the combinatorial approach 
was used.  
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Chapter 6: Summary 
A nanogel composed of a modified hyaluronic acid was synthesized for the delivery of 
potentially cytokines that may prove to be toxic in supraphyisological levels. This 
nanogel is 120 nm in diameter, and has shown the ability to accumulate at high levels in 
the tumor via intravenous injection. However, this nanogel also accumulates largely in 
the liver, indicating the need to investigate the toxicity of the therapeutic in its current 
state. The release of IL-12 from this nanogel is sustained over several days with a 
minimal burst release. The nanogel appears to have a small degree of enzymatically 
mediated degradation, which is thought to be largely determined by the degree of 
substitution of functional groups on the polymeric backbone of hyaluronic acid. The 
nanogel’s half life is comparable to existing drug delivery systems composed of 
hyaluronic acid, and may have potential for delivery via intravenous injection. Finally, 
the nanogel indicates some antitumor efficacy, and was able to significantly increase the 
number of tumor specific cytotoxic lymphocytes. All design criteria were met to some 
capacity, and the results reported here may provide a platform for novel delivery systems 
to enhance a particularly potent form of immunotherapy to treat aggressive cancers.  
 
Chapter 7: Conclusions 
7.1 General Conclusions 
After completing this study, it can be concluded the nanogel platform described here 
provides a unique ability to delivery potentially cytotoxic cytokines without their 
systemic side effects. Moreover, the environmental responsiveness of the nanogel allows 
for increased delivery specificity, and can be customized by altering the degree of 
substitution of the functional groups on the hyaluronic acid. The nanogel has shown the 
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ability to encapsulate biologically active cytokine, and was able to statistically increase 
the number of tumor specific cytotoxic lymphocytes in a mouse inoculated with a B16-
F10 melanoma tumor. Though not statistically significant, the combinatorial treatment of 
the IL-12 and anti PD1 was able to reduce the tumor’s growth rate, indicating efficacy 
against an aggressive cancer model. The circulation time of the nanogel is comparable to 
other hyaluronic acid based therapeutics, and the nanogel is able to accumulate in the 
tumor. However, the large uptake of the nanogel in the liver may be an indication to 
inject the therapeutic intratumorally, or provide a modification to reduce liver-specific 
interactions.   
 
7.2 Specific Aims & Design Criteria 
To conclude this study, the specific aims and design criteria are re-addressed. These aims 
are located in Chapter 2.5. Here, we report a nanogel that contains two potential 
mechanisms for environmental responsiveness. While statistically insignificant, the 
enzymatic degradation of the nanogel showed a faster initial release of IL-12. As 
previously discussed, the degree of substitution may be altered, increasing the 
degradability. Furthermore, the hypoxia sensitive release remains to be characterized. 
Though not significant, this design was able to show a delay in tumor growth in an 
aggressive melanoma model. Finally, the proposed combinatorial therapy significantly 
increased the number of tumor specific cytotoxic lymphocytes. This study addresses aims 
1 and 2, and achieves aim 3 with statistical significance.  
Similarly, the design criteria are re-addressed. These criteria can be found in Chapter 2.6. 
The nanogel was able to achieve an encapsulation efficiency of 73% for IL-12, and had a 
mean size of 120 nm and a PDI of 0.268. The nanogel achieved a half life of 7.3 hours 
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and was able to illustrate a larger differentiation capacity than recombinant human IL-12. 
The final criteria of the tumor containing the largest accumulation of the nanogel was not 
met. However, this can be attributed to interactions with Kupffer cells[40]. Several 
strategies have been considered to improve this issue.  
 
Chapter 8: Recommendations 
8.1 Co-encapsulation & Release Profile 
This study was able to show the successful encapsulation of IL-12, with an encapsulation 
efficiency of 73%. After illustrating the potential for a combinatorial approach with the 
nanogel, an improvement on this project could involve the encapsulation of antiPD1 
antibody in addition to IL-12.  AntiPD1 has shown clinical efficacy, but in excess can 
also cause autoimmunity [41]. Using the proposed nanogel DDS to properly control the 
administration of antiPD1 may be able to provide increase anti tumor efficacy with a 
lower dose. One study was able to illustrate the benefits of the sustained release of anti 
PD-1 using a microneedle patch delivery system [41]. Furthermore, the hypoxic 
responsive release of the 6-(2-nitroimidazole) hexylamine (NIHA), has been 
characterized by Yu et al. The release profile of the nanogel in a hypoxic environment 
has yet to be characterized due to time constraints. Upon continuation of this project, the 
hypoxic responsive release should be characterized and optimized by altering the degree 
of substitution of the NIHA group. The hypoxic response should not be characterized in 
isolation, however. By adding the recombinant hyaluronidase and adjusting the pH of the 
solution in addition to the hypoxic environment, the release profile of the nanogel can be 
most accurately simulated to the actual release in vivo.  
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8.2 Route of Administration 
The route of administration of the nanogel is a key parameter that needs to be identified. 
In its current state, the nanogel accumulates mostly in the liver. However, the second 
highest accumulation was in the tumor. If a further modification of the nanogel is to be 
made to avoid liver accumulation, such PEGylation, then intravenous administration may 
be considered. However, these modifications may further alter the half life and release 
profiles. An in vivo experiment should be performed to determine the anti-tumor efficacy 
of the nanogel via I.V administration to determine if there are significant changes in 
tumor specific lymphocytes and tumor burden. A liver toxicity panel and serum levels of 
cytokine such as IFNγ should also be investigated.  If the nanogel can be administered 
intravenously without toxicity and a decrease in therapeutic effect, the nanogel may be 
considered as highly clinically relevant. If toxicity through I.V administration causes the 
mice to similarly present the administration of recombinant protein, then the nanogels 
main advantages may be limited to the sustained release component, and should be 
delivered intratumorally. While not highly clinically relevant, bariatric surgeries less 
invasive, surgical access to the tumor is likely to outweigh the associated cytokine 
toxicity.  
 
8.3 Chemokine & Cytokine Selection  
The anti tumor efficacy of the nanogel though not significant, was able to show 
suppressed tumor growth rates of the tumor in a highly aggressive melanoma model. 
However, recent studies have shown that Natural Killer (NK) cells may be also needed to 
completely eliminate the tumor burden [7]. Melanoma has shown the ability to up/down 
regulate the Major Histocompatibility Complex (MHC) on the surface of tumor cells. By 
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down regulating the MHC complex, B16-F10 melanoma cells are capable of escaping T-
cell activity, and make them susceptible to NK cells that normally interpret the down 
regulation of the MHC molecule as a sign of viral infection [7]. To escape NK cell 
activity, the melanoma cells then re-upregulate the MHC complex, which makes them 
susceptible to T-cell activity [7].  Therefore, using the nanogel to deliver or co-deliver a 
cytokine such as interleukin-15 (IL-15) to promote NK cell activity, may achieve 
complete reduction of the tumor burden and “cure” the animals of disease [7].  
 
Chemokines such CXCL11 that interact with the CXCR3 receptor are used by the body 
to produce chemical signals that allow for the immune cells to hone to the sigh of injury 
or disease [30]. These cytokines were initially attempted to be encapsulated, but are too 
small to achieve the sustained release indicated by the IL-12 release curve. The use of 
these chemokines encapsulated in the nanogel may increase T-cell homing from 
peripheral blood and lymphoid tissues without causing the increased levels of IFNγ. 
Determining a way to correctly encapsulate these molecules with a sustained release 
could alleviate the risk of encapsulating IL-12 and any associated toxicity.  
 
8.4 Characterization of Other Immune Cells  
Finally, future work should include characterization of the amount of dendritic cells at the 
site of the tumor. IL-12 is normally secreted by antigen presenting cells (APCs) such 
dendritic cells, B-cells and even macrophages to skew T-cell differentiation [9]. 
Introducing an increased amount of IL-12 may provide a negative feedback mechanism 
that alters the activity of these APCs. It would be interesting and beneficial to determine 
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any changes in phenotype, cytokine secretion, and proliferative rates of these cells to 
fully understand the effects of this immunotherapy.  
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